当前位置: 首页 >> 检索结果
共有 4962 条符合本次的查询结果, 用时 2.6142849 秒

341. Increasing walking capacity in patients with peripheral artery disease.

作者: Joshua A Beckman.;Mark A Creager.
来源: Lancet. 2025年405卷10489期1556-1557页

342. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.

作者: Marc P Bonaca.;Andrei-Mircea Catarig.;Kim Houlind.;Bernhard Ludvik.;Joakim Nordanstig.;Chethana Kalmady Ramesh.;Neda Rasouli.;Harald Sourij.;Alex Videmark.;Subodh Verma.; .
来源: Lancet. 2025年405卷10489期1580-1593页
Peripheral artery disease is a highly morbid type of atherosclerotic vascular disease involving the legs and is estimated to affect over 230 million individuals globally. Few therapies improve functional capacity and health-related quality of life in people with lower limb peripheral artery disease. We aimed to evaluate whether semaglutide improves function as measured by walking ability as well as symptoms, quality of life, and outcomes in people with peripheral artery disease and type 2 diabetes.

343. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.

作者: Jason S Richardson.;Deborah M Anderson.;Jason Mendy.;Lauren C Tindale.;Sufia Muhammad.;Tobi Loreth.;Sarah Royalty Tredo.;Kelly L Warfield.;Roshan Ramanathan.;Jorge T Caso.;Victoria A Jenkins.;Patrick Ajiboye.;Lisa Bedell.; .
来源: Lancet. 2025年405卷10487期1343-1352页
Chikungunya disease is a growing global public health concern. Vimkunya (previously chikungunya virus virus-like particle vaccine, previously PXVX0317) is a single-dose, pre-filled syringe for intramuscular injection. Here, we report safety, tolerability, and immunogenicity data for Vimkunya versus placebo in healthy adolescents and adults aged 12-64 years, and evaluate lot-to-lot consistency.

344. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.

作者: Antoni Castells.;Enrique Quintero.;Luis Bujanda.;Susana Castán-Cameo.;Joaquín Cubiella.;José Díaz-Tasende.;Ángel Lanas.;Akiko Ono.;Miquel Serra-Burriel.;Eladio Frías-Arrocha.;Cristina Hernández.;Rodrigo Jover.;Montserrat Andreu.;Fernando Carballo.;Juan Diego Morillas.;Dolores Salas.;Raquel Almazán.;Inmaculada Alonso-Abreu.;Jesús M Banales.;Vicent Hernández.;Isabel Portillo.;Mercedes Vanaclocha-Espí.;Mariola de la Vega.; .
来源: Lancet. 2025年405卷10486期1231-1239页
Colonoscopy and the faecal immunochemical test are accepted strategies for colorectal cancer screening in the average-risk population (ie, people aged ≥50 years without personal or family history of colorectal cancer). In this trial, we aimed to compare whether invitation to screening with faecal immunochemical test was non-inferior to colonoscopy in a screening programme.

345. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.

作者: Lauren C Tindale.;Jason S Richardson.;Deborah M Anderson.;Jason Mendy.;Sufia Muhammad.;Tobi Loreth.;Sarah Royalty Tredo.;Roshan Ramanathan.;Victoria A Jenkins.;Lisa Bedell.;Patrick Ajiboye.; .
来源: Lancet. 2025年405卷10487期1353-1361页
Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death.

346. Sudan's war and the burden of HIV: a call for urgent intervention.

作者: Ahmad Mohammad Al Zamel.;Ali Awadallah Saeed.;Mazin Elmubarak.
来源: Lancet. 2025年405卷10486期1223-1224页

347. First head-to-head trial of colonoscopy versus faecal testing for colorectal cancer screening.

作者: Michael Bretthauer.;Mette Kalager.
来源: Lancet. 2025年405卷10486期1204-1206页

348. An urgent call for the cessation of hostilities in the Middle East.

作者: Raya Leibowitz.;Michal Feldon.;Danny Rosin.
来源: Lancet. 2025年405卷10486期1223页

349. Prince Karim Aga Khan IV.

作者: Talha Burki.
来源: Lancet. 2025年405卷10484期1048页

350. Neuroprotective mechanisms of exercise and the importance of fitness for healthy brain ageing.

作者: Atefe R Tari.;Tara L Walker.;Aleksi M Huuha.;Sigrid B Sando.;Ulrik Wisloff.
来源: Lancet. 2025年405卷10484期1093-1118页
Ageing is a scientifically fascinating and complex biological occurrence characterised by morphological and functional changes due to accumulated molecular and cellular damage impairing tissue and organ function. Ageing is often accompanied by cognitive decline but is also the biggest known risk factor for Alzheimer's disease, the most common form of dementia. Emerging evidence suggests that sedentary and unhealthy lifestyles accelerate brain ageing, while regular physical activity, high cardiorespiratory fitness (CRF), or a combination of both, can mitigate cognitive impairment and reduce dementia risk. The purpose of this Review is to explore the neuroprotective mechanisms of endurance exercise and highlight the importance of CRF in promoting healthy brain ageing. Key findings show how CRF mediates the neuroprotective effects of exercise via mechanisms such as improved cerebral blood flow, reduced inflammation, and enhanced neuroplasticity. We summarise evidence supporting the integration of endurance exercise that enhances CRF into public health initiatives as a preventive measure against age-related cognitive decline. Additionally, we address important challenges such as lack of long-term studies with harmonised study designs across preclinical and clinical settings, employing carefully controlled and repeatable exercise protocols, and outline directions for future research.

353. Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors' reply.

作者: José Manuel Pérez-García.;Géraldine Gebhart.;Jose Rodríguez-Morató.;Antonio Llombart-Cussac.;Javier Cortés.
来源: Lancet. 2025年405卷10484期1055-1056页

354. COVID-19: border closures violate human rights - Authors' reply.

作者: Lawrence O Gostin.;Eric A Friedman.;Ames Dhai.;Saman Zia-Zarifi.
来源: Lancet. 2025年405卷10484期1054页

355. Neoadjuvant therapy in HER2-positive breast cancer and interim PET.

作者: Elif Hindié.;David Groheux.
来源: Lancet. 2025年405卷10484期1054-1055页

356. Private actors and governance for planetary health equity.

作者: Sharon Friel.
来源: Lancet. 2025年405卷10484期1053页

357. COVID-19: border closures violate human rights.

作者: Diego S Silva.;Oliver Razum.
来源: Lancet. 2025年405卷10484期1053-1054页

358. Decolonising global health funding: local leadership for global impact.

作者: Harini Arumugasamy.;Saravanan Sekaran.
来源: Lancet. 2025年405卷10484期1052-1053页

359. Tackling health disinformation in conflict settings.

作者: Gemma Bowsher.;Richard Sullivan.;Filippa Lentzos.
来源: Lancet. 2025年405卷10484期1052页

360. Ethical challenges in cancer registries: public benefits and patient rights.

作者: Prasanta Raghab Mohapatra.
来源: Lancet. 2025年405卷10484期1051-1052页
共有 4962 条符合本次的查询结果, 用时 2.6142849 秒